Clearance of Sclerostin, Osteocalcin, Fibroblast Growth Factor 23, and Osteoprotegerin by Dialysis
Overview
Affiliations
Introduction: Fibroblast growth factor (FGF23), sclerostin, osteocalcin, and osteoprotegerin are important factors that control mineral bone metabolism. End-stage renal disease is associated with the pronounced dysregulation of mineral bone metabolism; however, the impact and clearance of mineral bone metabolism factors during dialysis remain largely undescribed.
Methods: In a cross-sectional study, 10 chronic hemodialysis patients were treated with hemodialysis for 8 h using a high-flux filter and a dialysate bath of 50% calculated total body water continuously recycled at a rate of 500 mL/min. Plasma and dialysate concentrations of FGF23, sclerostin, osteoprotegerin, and osteocalcin were measured at 1, 2, 4, 6, and 8 h permitting the estimation of dialysis clearance.
Results: Clearance of FGF23 was 7.7 mL/min, of sclerostin was 7.6 mL/min, of osteoprotegerin was 1.2 mL/min, and of osteocalcin was 19.7 mL/min. Clearance of FGF23 was correlated to sclerostin and osteoprotegerin clearance and also to the ultrafiltration rate. Although, osteocalcin blood concentrations decreased during dialysis, they rebounded within 6 h. Overall, no significant changes in blood concentrations of the measure mineral bone metabolism factors were observed.
Conclusions: The intradialytic clearance of osteocalcin, FGF23, sclerostin, and osteoprotegerin occurs; however, only clearance of FGF23 is directly correlated with the ultrafiltration rate. The effects of dialytic clearance on mineral bone metabolism are, however, uncertain and intradialytic plasma concentrations of the studied substrates remained largely unchanged.
Plasma FGF23 is associated with left atrial remodeling in children on hemodialysis.
Sharma S, Patel N, Hanudel M, Ix J, Salusky I, Nguyen K Pediatr Nephrol. 2022; 38(7):2179-2187.
PMID: 36508050 PMC: 10247494. DOI: 10.1007/s00467-022-05812-x.
The Emerging Role of Bone-Derived Hormones in Diabetes Mellitus and Diabetic Kidney Disease.
Li Y, Gu Z, Wang J, Wang Y, Chen X, Dong B Front Endocrinol (Lausanne). 2022; 13:938830.
PMID: 35966090 PMC: 9367194. DOI: 10.3389/fendo.2022.938830.
Fischer D, Smith C, de Zan F, Bacchetta J, Bakkaloglu S, Agbas A Kidney Int Rep. 2021; 6(9):2358-2370.
PMID: 34514197 PMC: 8418977. DOI: 10.1016/j.ekir.2021.06.025.
Li S, Zhang Z, He D, He A, Liu Q Ther Adv Chronic Dis. 2021; 12:2040622320967148.
PMID: 34471512 PMC: 8404645. DOI: 10.1177/2040622320967148.
Kern A, Stompor T, Kiewisz J, Krazinski B, Kiezun J, Kiezun M J Pers Med. 2021; 11(3).
PMID: 33800939 PMC: 8001826. DOI: 10.3390/jpm11030186.